DOCSLIB.ORG

Full-Text.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Downloaded from http://www.jimmunol.org/ by guest on September 30, 2021 is online at: average * The Journal of Immunology , 12 of which you can access for free at: 2012; 189:1920-1927; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication July 2012; doi: 10.4049/jimmunol.1103373 http://www.jimmunol.org/content/189/4/1920 Increased Immune Gene Expression and Immune Cell Infiltration in High-Grade Astrocytoma Distinguish Long-Term from Short-Term Survivors Andrew M. Donson, Diane K. Birks, Stephanie A. Schittone, Bette K. Kleinschmidt-DeMasters, Derrick Y. Sun, Molly F. Hemenway, Michael H. Handler, Allen E. Waziri, Michael Wang and Nicholas K. Foreman J Immunol cites 41 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/07/16/jimmunol.110337 3.DC1 This article http://www.jimmunol.org/content/189/4/1920.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 30, 2021. The Journal of Immunology Increased Immune Gene Expression and Immune Cell Infiltration in High-Grade Astrocytoma Distinguish Long-Term from Short-Term Survivors Andrew M. Donson,*,† Diane K. Birks,†,‡ Stephanie A. Schittone,*,† Bette K. Kleinschmidt-DeMasters,x,{ Derrick Y. Sun,‡ Molly F. Hemenway,*,† Michael H. Handler,†,‡ Allen E. Waziri,‡ Michael Wang,*,† and Nicholas K. Foreman*,†,‡ Survival in the majority of high-grade astrocytoma (HGA) patients is very poor, with only a rare population of long-term survivors. A better understanding of the biological factors associated with long-term survival in HGAwould aid development of more effective therapy and survival prediction. Factors associated with long-term survival have not been extensively studied using unbiased genome-wide expression analyses. In the current study, gene expression microarray profiles of HGA from long-term survivors were Downloaded from interrogated for discovery of survival-associated biological factors. Ontology analyses revealed that increased expression of immune function-related genes was the predominant biological factor that positively correlated with longer survival. A notable T cell sig- nature was present within this prognostic immune gene set. Using immune cell-specific gene classifiers, both T cell-associated and myeloid linage-associated genes were shown to be enriched in HGA from long-term versus short-term survivors. Association of immune function and cell-specific genes with survival was confirmed independently in a larger publicly available glioblastoma gene expression microarray data set. Histology was used to validate the results of microarray analyses in a larger cohort of long- http://www.jimmunol.org/ term survivors of HGA. Multivariate analyses demonstrated that increased immune cell infiltration was a significant independent variable contributing to longer survival, as was Karnofsky/Lansky performance score. These data provide evidence of a prognostic anti-tumor adaptive immune response and rationale for future development of immunotherapy in HGA. The Journal of Immu- nology, 2012, 189: 1920–1927. edian survival in high-grade astrocytoma (HGA), con- mutational status have been established as molecular prognostic sisting predominantly of glioblastoma (GBM) and an- factors in adult HGA (4, 5). M aplastic astrocytoma (AA), is 15 mo and 3 y, respectively Gene expression microarray analyses have been used to identify by guest on September 30, 2021 (1, 2). Few robust prognostic factors have been identified in HGA, novel prognostic biomarkers in HGA. This unbiased genome-wide hindering patient care and stratification in clinical trials. Currently approach has the additional benefit of providing insight into the established clinical risk factors include Karnofsky/Lansky perfor- biological mechanisms of tumorigenesis that can be exploited for mance score, a measure of patient well-being that is widely used in the development of more effective therapies. Despite numerous oncology, and age (3). O-6-Methylguanine-DNA methyltransfer- studies that have identified prognostic gene signatures in HGA ase promoter methylation status and isocitrate dehydrogenase 1 using microarray technology, there remains no predictor of survival that has proved robustly reproducible from study to study (6–10). This may be due to the effects of biological heterogeneity inherent *Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045; in HGA combined with the typically limited duration and range of †The Children’s Hospital, Aurora, CO 80045; ‡Department of Neurosurgery, Univer- survival. sity of Colorado Denver, Aurora, CO 80045; xDepartment of Pathology, University of Colorado Denver, Aurora, CO 80045; and {Department of Neurology, University of Although prognosis is poor for the majority of HGA, a small Colorado Denver, Aurora, CO 80045 but discrete subgroup of long-term survivors exists, with 3–5% of Received for publication November 23, 2011. Accepted for publication June 17, GBM patients surviving longer than 3 y. The driving hypothesis 2012. for this study is that a more pronounced and biologically infor- This work was supported by the Morgan Adams Foundation and by National Insti- mative prognostic gene signature could be obtained by gene ex- tutes of Health Grant R01 CA140614-01A1. pression microarray analysis of long-term survivors of HGA. Using The sequences presented in this article have been submitted to the Gene Expression this approach, the current study identified immune function as the Omnibus (http://www.ncbi.nlm.nih.gov/geo/) database under accession number GSE33331. predominant ontology associated with long-term survival in pe- Address correspondence and reprint requests to Andrew M. Donson, Department of diatric and adult HGA. Histological validation in a larger cohort Pediatrics, University of Colorado Denver, Mail Stop 8302, Building RC1, 12800 E. of long-term survivors demonstrated that increased infiltration of 19th Avenue, Aurora, CO 80045. E-mail address: [email protected] immune cells was prognostically favorable. The online version of this article contains supplemental material. Abbreviations used in this article: AA, anaplastic astrocytoma; AIF1, allograft inhibi- tory factor-1; DAVID, Database for Annotation, Visualization, and Integrated Discov- Materials and Methods ery; EPN, ependymoma; FFPE, formalin-fixed paraffin-embedded; GBM, glioblastoma; Patient cohort and sample collection gcRMA, guanine cytosine Robust Multiarray Average; GO, Gene Ontology Project; GSEA, Gene Set Enrichment Analysis; HGA, high-grade astrocytoma; IHC, immuno- Both adult and pediatric HGA samples, including GBM and AA, were histochemistry. included in this study cohort. Using broad age and diagnostic categories substantially increased the number of long-term survivors available to the Copyright Ó 2012 by The American Association of Immunologists, Inc. 0022-1767/12/$16.00 study. This inclusive approach also has the potential to identify broad www.jimmunol.org/cgi/doi/10.4049/jimmunol.1103373 The Journal of Immunology 1921 prognostic factors in HGA. Multivariate analyses were used to address the variable. GSEA creates a ranked list of genes based on user-selected cri- confounding effect of age, tumor grade, and a number of other potentially teria such as signal-to-noise, t tests, and so forth. For the purposes of this prognostic factors in this cohort. study, genes were ranked on their correlation with survival time. Thus, For the initial discovery cohort (gene expression microarray analysis), unlike DAVID, GSEA takes into account the strength of association rather surgical tumor samples were obtained from 26 patients who presented than simply whether a gene is significantly associated or not. The output between 1990 and 2008 for treatment of HGA at the University Hospital or for both ontology analysis tools is an enrichment score with associated The Children’s Hospital (Aurora, CO) who were diagnosed with GBM or Student t test p values for each GO term. AA according to World Health Organization guidelines (11). Tumor was either snap frozen in liquid nitrogen or placed in RNAlater storage solu- Enrichment analysis of specific immune cell lineage genes tion (Qiagen, Valencia, CA) at the time of resection. Survival data were Gene expression microarray data derived from surgical brain tumor speci- available for all patients in this study, which was conducted in compliance mens contain genes expressed by nontumor cells of the tumor microenvi- with institutional review board regulations (COMIRB 95-500 and 05- ronment. To address this, a technique was developed to identify and predict 0149). Included in this study were three long-term HGA survivors (two specific expression patterns of immune-related cells, based on data from adult GBM and one pediatric GBM), with a median survival of 7.0
Recommended publications
  • Sequence Analysis and Comparative Study of the Protein Subunits of Archaeal Rnase P

    Sequence Analysis and Comparative Study of the Protein Subunits of Archaeal Rnase P

    biomolecules Review Sequence Analysis and Comparative Study of the Protein Subunits of Archaeal RNase P Manoj P. Samanta 1,*,†, Stella M. Lai 2,3,†, Charles J. Daniels 3,4 and Venkat Gopalan 2,3,* 1 Systemix Institute, Redmond, WA 98053, USA 2 Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH 43210, USA; [email protected] 3 Center for RNA Biology, The Ohio State University, Columbus, OH 43210, USA; [email protected] 4 Department of Microbiology, The Ohio State University, Columbus, OH 43210, USA * Correspondence: [email protected] (M.P.S.); [email protected] (V.G.); Tel.: +1-425-898-8187 (M.P.S.); +1-614-292-1332 (V.G.) † These authors contributed equally to this work. Academic Editor: Denis Drainas Received: 1 March 2016; Accepted: 8 April 2016; Published: 20 April 2016 Abstract: RNase P, a ribozyme-based ribonucleoprotein (RNP) complex that catalyzes tRNA 51-maturation, is ubiquitous in all domains of life, but the evolution of its protein components (RNase P proteins, RPPs) is not well understood. Archaeal RPPs may provide clues on how the complex evolved from an ancient ribozyme to an RNP with multiple archaeal and eukaryotic (homologous) RPPs, which are unrelated to the single bacterial RPP. Here, we analyzed the sequence and structure of archaeal RPPs from over 600 available genomes. All five RPPs are found in eight archaeal phyla, suggesting that these RPPs arose early in archaeal evolutionary history. The putative ancestral genomic loci of archaeal RPPs include genes encoding several members of ribosome, exosome, and proteasome complexes, which may indicate coevolution/coordinate regulation of RNase P with other core cellular machineries.
  • Mast Cells Promote Seasonal White Adipose Beiging in Humans

    Mast Cells Promote Seasonal White Adipose Beiging in Humans

    Diabetes Volume 66, May 2017 1237 Mast Cells Promote Seasonal White Adipose Beiging in Humans Brian S. Finlin,1 Beibei Zhu,1 Amy L. Confides,2 Philip M. Westgate,3 Brianna D. Harfmann,1 Esther E. Dupont-Versteegden,2 and Philip A. Kern1 Diabetes 2017;66:1237–1246 | DOI: 10.2337/db16-1057 Human subcutaneous (SC) white adipose tissue (WAT) localized to the neck and thorax of humans (4–8), and in a increases the expression of beige adipocyte genes in the process known as beiging (9), UCP1-positive adipocytes winter. Studies in rodents suggest that a number of form in subcutaneous (SC) white adipose tissue (WAT) immune mediators are important in the beiging response. (10). Beige adipocytes have unique developmental origins, We studied the seasonal beiging response in SC WAT gene signatures, and functional properties, including being from lean humans. We measured the gene expression of highly inducible to increase UCP1 in response to catechol- various immune cell markers and performed multivariate amines (9,11–13). Although questions exist about whether analysis of the gene expression data to identify genes beige fat can make a meaningful contribution to energy OBESITY STUDIES that predict UCP1. Interleukin (IL)-4 and, unexpectedly, expenditure in humans (reviewed in Porter et al. [14]), the mast cell marker CPA3 predicted UCP1 gene expres- the induction of beige fat in rodent models is associated sion. Therefore, we investigated the effects of mast with increased energy expenditure and improved glucose cells on UCP1 induction by adipocytes. TIB64 mast cells homeostasis (13). responded to cold by releasing histamine and IL-4, and this medium stimulated UCP1 expression and lipolysis by Activation of the sympathetic nervous system by cold 3T3-L1 adipocytes.
  • The Mineralocorticoid Receptor Leads to Increased Expression of EGFR

    The Mineralocorticoid Receptor Leads to Increased Expression of EGFR

    www.nature.com/scientificreports OPEN The mineralocorticoid receptor leads to increased expression of EGFR and T‑type calcium channels that support HL‑1 cell hypertrophy Katharina Stroedecke1,2, Sandra Meinel1,2, Fritz Markwardt1, Udo Kloeckner1, Nicole Straetz1, Katja Quarch1, Barbara Schreier1, Michael Kopf1, Michael Gekle1 & Claudia Grossmann1* The EGF receptor (EGFR) has been extensively studied in tumor biology and recently a role in cardiovascular pathophysiology was suggested. The mineralocorticoid receptor (MR) is an important efector of the renin–angiotensin–aldosterone‑system and elicits pathophysiological efects in the cardiovascular system; however, the underlying molecular mechanisms are unclear. Our aim was to investigate the importance of EGFR for MR‑mediated cardiovascular pathophysiology because MR is known to induce EGFR expression. We identifed a SNP within the EGFR promoter that modulates MR‑induced EGFR expression. In RNA‑sequencing and qPCR experiments in heart tissue of EGFR KO and WT mice, changes in EGFR abundance led to diferential expression of cardiac ion channels, especially of the T‑type calcium channel CACNA1H. Accordingly, CACNA1H expression was increased in WT mice after in vivo MR activation by aldosterone but not in respective EGFR KO mice. Aldosterone‑ and EGF‑responsiveness of CACNA1H expression was confrmed in HL‑1 cells by Western blot and by measuring peak current density of T‑type calcium channels. Aldosterone‑induced CACNA1H protein expression could be abrogated by the EGFR inhibitor AG1478. Furthermore, inhibition of T‑type calcium channels with mibefradil or ML218 reduced diameter, volume and BNP levels in HL‑1 cells. In conclusion the MR regulates EGFR and CACNA1H expression, which has an efect on HL‑1 cell diameter, and the extent of this regulation seems to depend on the SNP‑216 (G/T) genotype.
  • Two Locus Inheritance of Non-Syndromic Midline Craniosynostosis Via Rare SMAD6 and 4 Common BMP2 Alleles 5 6 Andrew T

    Two Locus Inheritance of Non-Syndromic Midline Craniosynostosis Via Rare SMAD6 and 4 Common BMP2 Alleles 5 6 Andrew T

    1 2 3 Two locus inheritance of non-syndromic midline craniosynostosis via rare SMAD6 and 4 common BMP2 alleles 5 6 Andrew T. Timberlake1-3, Jungmin Choi1,2, Samir Zaidi1,2, Qiongshi Lu4, Carol Nelson- 7 Williams1,2, Eric D. Brooks3, Kaya Bilguvar1,5, Irina Tikhonova5, Shrikant Mane1,5, Jenny F. 8 Yang3, Rajendra Sawh-Martinez3, Sarah Persing3, Elizabeth G. Zellner3, Erin Loring1,2,5, Carolyn 9 Chuang3, Amy Galm6, Peter W. Hashim3, Derek M. Steinbacher3, Michael L. DiLuna7, Charles 10 C. Duncan7, Kevin A. Pelphrey8, Hongyu Zhao4, John A. Persing3, Richard P. Lifton1,2,5,9 11 12 1Department of Genetics, Yale University School of Medicine, New Haven, CT, USA 13 2Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA 14 3Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA 15 4Department of Biostatistics, Yale University School of Medicine, New Haven, CT, USA 16 5Yale Center for Genome Analysis, New Haven, CT, USA 17 6Craniosynostosis and Positional Plagiocephaly Support, New York, NY, USA 18 7Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, USA 19 8Child Study Center, Yale University School of Medicine, New Haven, CT, USA 20 9The Rockefeller University, New York, NY, USA 21 22 ABSTRACT 23 Premature fusion of the cranial sutures (craniosynostosis), affecting 1 in 2,000 24 newborns, is treated surgically in infancy to prevent adverse neurologic outcomes. To 25 identify mutations contributing to common non-syndromic midline (sagittal and metopic) 26 craniosynostosis, we performed exome sequencing of 132 parent-offspring trios and 59 27 additional probands.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short

    Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short

    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
  • Genome-Wide Analysis of Androgen Receptor Binding and Gene Regulation in Two CWR22-Derived Prostate Cancer Cell Lines

    Genome-Wide Analysis of Androgen Receptor Binding and Gene Regulation in Two CWR22-Derived Prostate Cancer Cell Lines

    Endocrine-Related Cancer (2010) 17 857–873 Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines Honglin Chen1, Stephen J Libertini1,4, Michael George1, Satya Dandekar1, Clifford G Tepper 2, Bushra Al-Bataina1, Hsing-Jien Kung2,3, Paramita M Ghosh2,3 and Maria Mudryj1,4 1Department of Medical Microbiology and Immunology, University of California Davis, 3147 Tupper Hall, Davis, California 95616, USA 2Division of Basic Sciences, Department of Biochemistry and Molecular Medicine, Cancer Center and 3Department of Urology, University of California Davis, Sacramento, California 95817, USA 4Veterans Affairs Northern California Health Care System, Mather, California 95655, USA (Correspondence should be addressed to M Mudryj at Department of Medical Microbiology and Immunology, University of California, Davis; Email: [email protected]) Abstract Prostate carcinoma (CaP) is a heterogeneous multifocal disease where gene expression and regulation are altered not only with disease progression but also between metastatic lesions. The androgen receptor (AR) regulates the growth of metastatic CaPs; however, sensitivity to androgen ablation is short lived, yielding to emergence of castrate-resistant CaP (CRCaP). CRCaP prostate cancers continue to express the AR, a pivotal prostate regulator, but it is not known whether the AR targets similar or different genes in different castrate-resistant cells. In this study, we investigated AR binding and AR-dependent transcription in two related castrate-resistant cell lines derived from androgen-dependent CWR22-relapsed tumors: CWR22Rv1 (Rv1) and CWR-R1 (R1). Expression microarray analysis revealed that R1 and Rv1 cells had significantly different gene expression profiles individually and in response to androgen.
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
  • SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation–Specific Fusion Transcript in Prostate Cancer

    SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation–Specific Fusion Transcript in Prostate Cancer

    Published OnlineFirst March 17, 2009; DOI: 10.1158/0008-5472.CAN-08-4926 Priority Report SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation–Specific Fusion Transcript in Prostate Cancer David S. Rickman,1 Dorothee Pflueger,1 Benjamin Moss,1 Vanessa E. VanDoren,1 Chen X. Chen,1 Alexandre de la Taille,4,5 Rainer Kuefer,6 Ashutosh K. Tewari,2 Sunita R. Setlur,7 Francesca Demichelis,1,3 and Mark A. Rubin1 Departments of 1Pathology and Laboratory Medicine and 2Urology, and 3Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York; 4Department of Urology, CHU Mondor and 5Institut National de la Sante et de la Recherche Medicale, Unite´841, Cre´teil,France; 6Department of Urology, University Hospital Ulm, Ulm, Germany; and 7Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Abstract (2, 3), and a specific expression profile (4, 5). Androgen-regulated ¶ Chromosomal rearrangements account for all erythroblast genes account for the majority of the 5 genomic regulatory transformation–specific (ETS) family member gene fusions promoters elements fused with ETS genes in prostate cancer (6). The promoter of the androgen-regulated transmembrane protease, that have been reported in prostate cancer and have clinical, serine 2 TMPRSS2 diagnostic, and prognostic implications. Androgen-regulated ( ) gene is fused to the coding region of members genes account for the majority of the 5¶ genomic regulatory of the ETS family of transcription factors, most commonly v-ets TMPRSS2-ERG, erythroblastosis virus E26 oncogene homologue (avian; ERG; ref. 7). promoter elements fused with ETS genes. Solute carrier family 45, member 3 SLC45A3 TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account ( ), also referred to as for roughly 90% of ETS fusion prostate cancer.
  • Metastatic Adrenocortical Carcinoma Displays Higher Mutation Rate and Tumor Heterogeneity Than Primary Tumors

    Metastatic Adrenocortical Carcinoma Displays Higher Mutation Rate and Tumor Heterogeneity Than Primary Tumors

    ARTICLE DOI: 10.1038/s41467-018-06366-z OPEN Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors Sudheer Kumar Gara1, Justin Lack2, Lisa Zhang1, Emerson Harris1, Margaret Cam2 & Electron Kebebew1,3 Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is 1234567890():,; unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs. 1 Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 2 Center for Cancer Research, Collaborative Bioinformatics Resource, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 3 Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. Correspondence and requests for materials should be addressed to E.K. (email: [email protected]) NATURE COMMUNICATIONS | (2018) 9:4172 | DOI: 10.1038/s41467-018-06366-z | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06366-z drenocortical carcinoma (ACC) is a rare malignancy with types including primary ACC from the TCGA to understand our A0.7–2 cases per million per year1,2.
  • Transcriptomic and Proteomic Profiling Provides Insight Into

    Transcriptomic and Proteomic Profiling Provides Insight Into

    BASIC RESEARCH www.jasn.org Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy † † ‡ Peidi Liu,* Emelie Lassén,* Viji Nair, Celine C. Berthier, Miyuki Suguro, Carina Sihlbom,§ † | † Matthias Kretzler, Christer Betsholtz, ¶ Börje Haraldsson,* Wenjun Ju, Kerstin Ebefors,* and Jenny Nyström* *Department of Physiology, Institute of Neuroscience and Physiology, §Proteomics Core Facility at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden; †Division of Nephrology, Department of Internal Medicine and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan; ‡Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan; |Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; and ¶Integrated Cardio Metabolic Centre, Karolinska Institutet Novum, Huddinge, Sweden ABSTRACT IgA nephropathy (IgAN), the most common GN worldwide, is characterized by circulating galactose-deficient IgA (gd-IgA) that forms immune complexes. The immune complexes are deposited in the glomerular mesangium, leading to inflammation and loss of renal function, but the complete pathophysiology of the disease is not understood. Using an integrated global transcriptomic and proteomic profiling approach, we investigated the role of the mesangium in the onset and progression of IgAN. Global gene expression was investigated by microarray analysis of the glomerular compartment of renal biopsy specimens from patients with IgAN (n=19) and controls (n=22). Using curated glomerular cell type–specific genes from the published literature, we found differential expression of a much higher percentage of mesangial cell–positive standard genes than podocyte-positive standard genes in IgAN. Principal coordinate analysis of expression data revealed clear separation of patient and control samples on the basis of mesangial but not podocyte cell–positive standard genes.
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids

    Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids

    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,